

## GU ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
SWOG	S1500-pRCC,Adv, Sunitinib vs MET inhib	1 Y	1 Sunitinib	180	20	11	6	2	1	0	07/25/2016	225	96
			2 Cabozantinib		18	10	6	3	0	0			
			3 Crizotinib		21	13	8	4	2	2			
			4 Savolitinib		20	11	7	3	1	1			
					79	45	27	12	4	3			
	S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1 Y	1 TICE BCG	969	32	29	17	9	3	0	02/24/2017	148	63
			2 Tokyo-172 BCG		31	29	17	10	5	1			
			3 Prime + Tokyo-172 BCG		29	28	15	8	3	0			
					92	86	49	27	11	1			
	S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab	1 Y	1 Atezolizumab	148	41	39	25	10	2	1	03/13/2017	159	71
					41	39	25	10	2	1			
Yes	A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	1 E	Total Registrations		3	1	1	1	0	0	11/23/2016	60	33
					3	1	1	1	0	0			
	EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER)	0 E	Total Registrations		15	15	12	8	3	1	09/29/2017		38
					15	15	12	8	3	1			
			1 E		Total Registrations	11	11	8	5	1			
					11	11	8	5	1	0			
	NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel	1 E	Total Registrations		1	1	0	0	0	0	08/24/2017		123
					1	1	0	0	0	0			
					1	1	0	0	0	0			
		2 E	Total Registrations		1	1	0	0	0	0	08/24/2017		
					1	1	0	0	0	0			
					1	1	0	0	0	0			
No	R0924-Pros, NADT+WPRT vs. NADT+P&SV RT	1 E	Total Registrations		72	30	16	8	0	0	11/25/2013		176
					72	30	16	8	0	0			
					72	30	16	8	0	0			